Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Study results point to efficacy of once-daily bimatoprost
Indianapolis-Pooled 6-month data from two multicenter, double-blind, parallel studies demonstrate that once-daily treatment with bimatoprost ophthalmic solution 0.03% (Lumigan, Allergan) is safe and more effective than timolol 0.5% for controlling elevated IOP, said Louis B. Cantor, MD.
Related Videos
Related Content
